BiotechTube

TILD sub-cutaneous (SC) injection

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Jun 30, 2022 → Apr 1, 2029

NCT ID
NCT04991116

About TILD sub-cutaneous (SC) injection

TILD sub-cutaneous (SC) injection is a phase 3 stage product being developed by Sun Pharmaceutical for Psoriatic Arthritis. The current trial status is active. This product is registered under clinical trial identifier NCT04991116. Target conditions include Psoriatic Arthritis.

What happened to similar drugs?

10 of 20 similar drugs in Psoriatic Arthritis were approved

Approved (10) Terminated (0) Active (10)
✅Ixekizumab + AdalimumabEli LillyApproved
✅TirzepatideEli LillyApproved
✅GuselkumabJohnson & JohnsonApproved
✅methotrexate (MTX) + adalimumab (ADA)AbbVieApproved
✅Upadacitinib 15 MG [Rinvoq] + PlaceboAbbVieApproved
✅Secukinumab 300 mg + Secukinumab 150 mgNovartisApproved
✅ApremilastAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04991116Phase 3Active

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + TirzepatideEli LillyPre-clinical
33
Ixekizumab + TirzepatideEli LillyPhase 3
44
Ixekizumab + AdalimumabEli LillyApproved
43
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
35
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
38
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
35
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
40
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
44
Ixekizumab + AdalimumabEli LillyPhase 3
44
TirzepatideEli LillyApproved
50
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
40
GuselkumabJohnson & JohnsonApproved
50
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
42
SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
36